Effectiveness of PARP Inhibitor Maintenance Therapy in Ovarian Cancer by BRCA1/2 and a Scar-Based HRD Signature in Real-World Practice.
Richardson DL, Quintanilha JCF, Danziger N, Li G, Sokol E, Schrock AB, Ebot E, Bhardwaj N, Norris T, Afghahi A, Frachioni A, Washington C, Dockery L, Elvin J, Graf RP, Moore KN.
Richardson DL, et al. Among authors: dockery l.
Clin Cancer Res. 2024 Oct 15;30(20):4644-4653. doi: 10.1158/1078-0432.CCR-24-1225.
Clin Cancer Res. 2024.
PMID: 39078736
Free PMC article.